Abstract

Various ion channels are expressed in human cancers where they are intimately involved in proliferation, angiogenesis, invasion and metastasis. Expression of functional voltage-gated Na(+) channels (Nav) is implicated in the metastatic potential of breast, prostate, lung and colon cancer cells. However, the cellular mechanisms that regulate Nav expression in cancer remain largely unknown. Growth factors are attractive candidates; they not only play crucial roles in cancer progression but are also key regulators of ion channel expression and activity in non-cancerous cells. Here, we examine the role of epidermal growth factor receptor (EGFR) signalling and Nav in non-small cell lung carcinoma (NSCLC) cell lines. We show unequivocally, that functional expression of the α subunit Nav1.7 promotes invasion in H460 NSCLC cells. Inhibition of Nav1.7 activity (using tetrodotoxin) or expression (by using small interfering RNA), reduces H460 cell invasion by up to 50%. Crucially, non-invasive wild type A549 cells lack functional Nav, whereas exogenous overexpression of the Nav1.7 α subunit is sufficient to promote TTX-sensitive invasion of these cells. EGF/EGFR signalling enhances proliferation, migration and invasion of H460 cells but we find that, specifically, EGFR-mediated upregulation of Nav1.7 is necessary for invasive behaviour in these cells. Examination of Nav1.7 expression at mRNA, protein and functional levels further reveals that EGF/EGFR signalling via the ERK1/2 pathway controls transcriptional regulation of channel expression to promote cellular invasion. Immunohistochemistry of patient biopsies confirms the clinical relevance of Nav1.7 expression in NSCLC. Thus, Nav1.7 has significant potential as a new target for therapeutic intervention and/or as a diagnostic or prognostic marker in NSCLC.

Highlights

  • Lung cancer is the most prevalent cancer world-wide

  • Two cell lines were selected for further study: A549 cells that lacked inward Nav current (INa) and H460 cells that exhibited the most-robust INa both in terms of current amplitude and proportion of cells with current (,45%, n589)

  • H460 cells were, chosen as a strongly invasive model, whereas A549 cells were used as a model of weak invasive potential

Read more

Summary

Introduction

Lung cancer is the most prevalent cancer world-wide. Small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC) occur with a frequency of ,20% and ,80%, respectively. NSCLC has a low, average 5-year, survival rate (14%) and the development of metastases results in extremely poor prognosis (Jemal et al, 2011). The epidermal growth factor receptor (EGFR) plays key roles in the progression of various cancers (Araujo et al, 2007; Cohen, 2002; Mendelsohn, 2003), and in NSCLC its overexpression in ,40–80% of patients is associated with poor prognosis (Mendelsohn, 2003). Smallmolecule EGFR kinase inhibitors (gefitinib and erlotinib) have recently shown significant therapeutic benefit in many patients with advanced NSCLC, those with somatic mutations of the EGFR (Araujo et al, 2007). There is a pressing need for improved treatments based upon improved understanding of the effector pathways downstream of EGFR signalling

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call